The underlying mechanism for the increased HR has not yet been fully elucidated
Recent Developments: 2025: Eli Lilly received FDA approval for tirzepatide (Zepbound) as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity the first pharmacotherapy approved for this indication expanding tirzepatide's approved uses beyond metabolic conditions into a respiratory indication affecting over 30 million Americans and supported by SURMOUNT-OSA trial data showing 63% reduction in apnea-hypopnea index
Myqorzo, chemically known as aficamten, reduces the forceful heart muscle contractions
DSIP is discussed when the goal is more restorative sleep, not just earlier sleep onset
From what weve seen so far, theres no problem there's no safety signal and there appears to be no contraindication at this time to using them, she says
These predispositions should be interpreted with a qualified healthcare provider as one component of a comprehensive evaluation, not as a guarantee of exact medication response or outcome